Welcome to PsorVal.net | DermaSolve.net !

 

Your Source for Psor-Val | DermaSolve | Absorbase

 

 Serving Treatment Solutions for Psoriasis, Eczema, Dry Skin 

 

Providing News, Views, Tips and Tricks

along with great products for that   "Healthy You" 

 

Looking for Psor-Val Spray? Click here 


*Buy Psor-Val on Amazon* Click here


 

Now Shipping Psor-Val Spray World Wide

 International Clients - Click "We Ship Worldwide!"

MedWorm: Psoriasis

New Drug on the Block: Apremilast for Plaque PsoriasisNew Drug on the Block: Apremilast for Plaque Psoriasis (Sat, 28 Feb 2015)
Will this new oral agent for plaque psoriasis provide the relief your patients need? Medscape Pharmacists (Source: Medscape Dermatology Headlines) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.
>> read more

Disseminated superficial actinic porokeratosis in a psoriasis patient with a long‐term sun‐bathing habit (Fri, 27 Feb 2015)
(Source: The Journal of Dermatology)
>> read more

Poor adherence to medication as assessed by the Morisky Medication Adherence Scale‐8 and low satisfaction with treatment in 237 psoriasis patients (Fri, 27 Feb 2015)
This study was conducted among patients registered in monitoring system and 3096 eligible patients were enrolled. Our web‐based questionnaire included the following items such as age, sex, annual income, main health‐care institution, experience of effectiveness by oral or topical medication, overall satisfaction with treatment, and MMAS‐8 for oral or topical medication. Mean adherence score by MMAS‐8 was 5.2 for oral and 4.3 for topical medication. More patients with psoriasis used a university hospital and fewer used a private clinic compared with those with the other skin disease patients. Experience of drug effectiveness by oral medication and overall satisfaction with treatment was lower in psoriasis patients than in other patients. In oral medication, significantly better adhe...
>> read more

Methotrexate Dosing Regimen for Plaque-type Psoriasis: A Systematic Review of the Use of Test-dose, Start-dose, Dosing Scheme, Dose Adjustments, Maximum Dose and Folic Acid Supplementation. (Fri, 27 Feb 2015)
Authors: Menting SP, Dekker PM, Limpens J, Hooft L, Spuls PI Abstract There is a range of methotrexate dosing regimens for psoriasis. This review summarizes the evidence for test-dose, start-dose, dosing scheme, dose adjustments, maximum dose and use of folic acid. A literature search for randomized controlled trials and guidelines was performed. Twenty-three randomized controlled trials (29 treatment groups) and 10 guidelines were included. Two treatment-groups used a test-dose, 5 guidelines recommend it. The methotrexate start-dose in randomized controlled trials varied from 5 to 25 mg/week, most commonly being either 7.5 mg or 15 mg. Guidelines vary from 5 to 15 mg/week. Methotrexate was administered as a single dose or in a Weinstein schedule in 15 and 11 treatment-groups, resp...
>> read more

Marshaling the body's own weapons against psoriasis (Thu, 26 Feb 2015)
A three-character code brings relief to patients with psoriasis and sheds light on complex immunoregulation processes: IL-4, an abbreviation for the endogenous signaling molecule Interleukin 4. The substance's ability to inhibit inflammation is well known, but its mechanism of action was not fully understood. Scientists have now shown in an animal model and in a study on patients how IL-4 helps against psoriasis at the molecular level. (Source: ScienceDaily Headlines)
>> read more

Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety. (Thu, 26 Feb 2015)
Authors: Xu Z, Davis HM, Zhou H Abstract Immune-mediated inflammatory diseases encompass a variety of different clinical syndromes, manifesting as either common diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD) and psoriasis, or rare diseases such as cryopyrin-associated periodic syndromes. The therapy for these diseases often involves the use of a wide range of drugs including nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, immunomodulators, and biologic therapies. Due to the abundance of relevant clinical data, this article provides a general overview on the clinical impact of the concomitant use of immunomodulators and biologic therapies, with a focus on anti-tumor necrosis factor-α agents (anti-TNFα), for the treatment of RA and Croh... MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.
>> read more

The skin microbiome: Associations between altered microbial communities and disease (Thu, 26 Feb 2015)
Abstract A single square centimetre of the human skin can contain up to one billion microorganisms. These diverse communities of bacteria, fungi, mites and viruses can provide protection against disease, but can also exacerbate skin lesions, promote disease and delay wound healing. This review addresses the current knowledge surrounding the healthy skin microbiome and examines how different alterations to the skin microbial communities can contribute to disease. Current methodologies are considered, changes in microbial diversity and colonisation by specific microorganisms are discussed in the context of atopic dermatitis, psoriasis, acne vulgaris and chronic wounds. The recent impact of modern Westernised lifestyles on the human skin microbiome is also examined, as well as the potential b...
>> read more

Glycyrrhizin Ameliorates Imiquimod-Induced Psoriasis-like Skin Lesions in BALB/c Mice and Inhibits TNF-α-Induced ICAM-1 Expression via NF-κB/MAPK in HaCaT Cells (Thu, 26 Feb 2015)
Conclusions: These results demonstrate that GL treatment ameliorates skin inflammation by inhibiting ICAM-1 expression via interference with the ERK/p38 MAPK and NF-#x03BA;B signaling pathways in keratinocytes. Therefore, GL can be used as an anti-psoriasis drug.Cell Physiol Biochem 2015;35:1335-1346 (Source: Cellular Physiology and Biochemistry)
>> read more

Marshaling the body's own weapons against psoriasis (Thu, 26 Feb 2015)
(Technische Universitaet Muenchen) A three-character code brings relief to patients with psoriasis and sheds light on complex immunoregulation processes: IL-4, an abbreviation for the endogenous signaling molecule Interleukin 4. The substance's ability to inhibit inflammation is well known, but its mechanism of action was not fully understood. Scientists from Technische Universität München and University of Tübingen have now shown in an animal model and in a study on patients how IL-4 helps against psoriasis at the molecular level. (Source: EurekAlert! - Medicine and Health)
>> read more

Biologic Response Modifiers and Pediatric Psoriasis (Thu, 26 Feb 2015)
Abstract The efficacy and safety of biologic response modifiers such as etanercept, adalimumab, infliximab, and ustekinumab have been demonstrated in the treatment of psoriasis in adults, but none are currently approved for the treatment of psoriasis in children in the United States, and only etanercept is approved for the treatment of psoriasis in children in the European Union. Through case reports, case series, and a large clinical trial of the use of etanercept, the literature supports the use of these agents to treat psoriasis in children. Data on the use of the tumor necrosis factor‐α antagonists etanercept, adalimumab, and infliximab in the treatment of other inflammatory diseases in children—namely Crohn's disease, juvenile arthritis, and uveitis—support their safety profile...
>> read more

 

Scan our QR Code to your Smart Phone / iPhone Users download QR Reader from Tap Media http://www.TapMedia.co.uk 

Real Time Web Analytics


International Clients, After adding products to Cart - Refresh your browser if you do not see the "International Checkout" Button

Psor-Val Zinc Spray, DermaSolve Psoriasis Care Products and

Absorbase Cream for Moisturizing Skin Care.

 

Treatment Solutions and Products for Psoriasis, Eczema, Dry Skin. Natural Care for that Healthy You!